Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5140132 | 0.88 | KDM4E (0.40) | CA12CA1CA9MEN1KMT2A | |
| SCHEMBL6333993 | 0.76 | MAOB (0.39) | MEN1KMT2ACYP1A2CYP3A4MAPT | |
| SCHEMBL3538088 | 0.76 | ALDH1A1 (0.33) | MEN1KMT2ACYP3A4MAPT | |
| SCHEMBL10514896 | 0.76 | L3MBTL1 (0.33) | KMT2ACYP3A4MAPT | |
| SCHEMBL2197293 | 0.73 | CALM1 (0.41) | CA12CA9MEN1KMT2AMAPT | |
| SCHEMBL2215928 | 0.72 | CA12 (0.43) | CA12CA1CA9MEN1KMT2A | |
| SCHEMBL7969760 | 0.69 | FAAH (0.39) | MAPT | |
| SCHEMBL445087 | 0.69 | KCNH2 (0.38) | MAPT | |
| SCHEMBL3092337 | 0.68 | TP53 (0.38) | MEN1KMT2ACYP1A2MAPT | |
| SCHEMBL1396390 | 0.67 | GABRA1 (0.31) | GABRA1GABRB2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146574-A1 | Heterocycle Substituted Carboxylic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC | 2008-06-19 | — | — | US | claimed |
| US-20050004114-A1 | Heterocycle substituted carboxylic acids | INSTITUTE FOR DIABETES DISCOVERY, L.L.C. | 2005-01-06 | — | — | US | claimed |
| US-3972877-A | Butadiene derivatives, process for their preparation and their use as optical brighteners | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-08-03 | — | — | US | claimed |
| US-20080146574-A1 | Heterocycle Substituted Carboxylic Acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC | 2008-06-19 | — | — | US | disclosed |
| US-7329680-B2 | Heterocycle substituted carboxylic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1814869-A2 | SUBSTITUTED AMINO ACIDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | The Institutes for Pharmaceutical Discovery, LLC (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006055725-A2 | SUBSTITUTED AMINO ACIDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2006-05-26 | — | — | WO | disclosed |
| EP-1622886-A2 | SUBSTITUTED AMINO CARBOXYLIC ACIDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE-1B | The Institutes for Pharmaceutical Discovery, LLC (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20050004114-A1 | Heterocycle substituted carboxylic acids | INSTITUTE FOR DIABETES DISCOVERY, L.L.C. | 2005-01-06 | — | — | US | disclosed |
| WO-2004099171-A2 | SUBSTITUTED AMINO CARBOXYLIC ACIDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE-1B | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2004-11-18 | — | — | WO | disclosed |
| US-3972877-A | Butadiene derivatives, process for their preparation and their use as optical brighteners | HOECHST AKTIENGESELLSCHAFT (DT) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004114-A1 | Heterocycle substituted carboxylic acids | PTPRC, PTPRS, PTPRJ | CA12 3400/4885CA1 2211/4885CA9 1752/4885 |
| US-20080146574-A1 | Heterocycle Substituted Carboxylic Acids | PTPRC, PTPRS, PTPRJ | CA12 3400/4885CA1 2211/4885CA9 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.